1416341-93-9

Basic information

• Product Name: 1,3,6',3''-tetraazido-5,2',4'',6''-di-O-benzylidene-3',4',2''-tri-O-p-methoxybenzylkanamycin A
• Synonyms: 1,3,6',3''-tetraazido-5,2',4'',6''-di-O-benzylidene-3',4',2''-tri-O-p-methoxybenzylkanamycin A
• CAS NO: 1416341-93-9
• Molecular Weight: 1125.16
• Mol File: 1416341-93-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,3,6',3''-tetraazido-5,2',4'',6''-di-O-benzylidene-3',4',2''-tri-O-p-methoxybenzylkanamycin A(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,6',3''-tetraazido-5,2',4'',6''-di-O-benzylidene-3',4',2''-tri-O-p-methoxybenzylkanamycin A(1416341-93-9)
• EPA Substance Registry System: 1,3,6',3''-tetraazido-5,2',4'',6''-di-O-benzylidene-3',4',2''-tri-O-p-methoxybenzylkanamycin A(1416341-93-9)

Safety Data

• Hazardous Substances Data: 1416341-93-9(Hazardous Substances Data)

Upstream product

• 1037515-73-3 1,3,6',3”-tetra-azido-kanamycin A 
• 3847-27-6 Kanamycin A sulfate 
• 1147358-84-6 1,3,6',3''-tetraazido-5,2',4'',6''-di-O-benzylidenekanamycin A 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1416341-94-0 C₄₂H₅₂N₁₂O₁₄ 
• 1416341-95-1 1,3,6',3''-tetraazido-4'',6''-O-benzylidene-3',4',2''-tri-O-p-methoxybenzylkanamycin A 
• 1416341-96-2 1,3,6',3''-tetraazido-4'',6''-O-benzylidene-3',4',2''-tri-O-p-methoxybenzyl-5,2'-di-O-allylkanamycin A 
• 1416341-97-3 1,3,6',3''-tetraazido-4'',6''-O-benzylidene-3',4',2''-tri-O-p-methoxybenzyl-5,2'-O-(but-2-en-1,4-diyl)kanamycin A 

Relevant articles and documents

Design, synthesis, and antibacterial activities of conformationally constrained kanamycin A derivatives

A series of conformationally constrained kanamycin A derivatives with a 2′-hydroxyl group in ring I and a 5-hydroxyl group in ring II tethered by carbon chains were designed and synthesized. Pivotal 5,2′-hydroxyl groups were exposed, and the kanamycin A intermediate was synthesized from 5, 2′, 4″, 6″-di-O-benzylidene-protected tetraazidokanamycin A. Cyclic kanamycin A derivatives with intramolecular 8-, 9-, 10-, and 11-membered ethers were then prepared by cesium carbonate mediated Williamson ether synthesis or a ring-closing metathesis reaction. The kanamycin A derivatives were assayed against both susceptible and resistant bacterial strains. Although no derivative showed better antibacterial activities than kanamycin A, the antibacterial activities of these cyclic kanamycin A derivatives indeed varied with the length of the bridge. Moreover, different variations of activities were observed between the susceptible and resistant bacterial strains. More tightly constrained derivative 2 with a one-carbon bridge showed better activity than the others against susceptible strains, but it was much less effective for resistant bacterial strains than derivative 3 with a two-carbon bridge and derivative 6 with an unsaturated four-carbon bridge.